Adjuvant Pelvic Radiotherapy vs. Sequential Chemoradiotherapy for High-Risk Stage I-II Endometrial Carcinoma

OBJECTIVE: To explore if the addition of adjuvant chemotherapy with paclitaxel and carboplatin to radiotherapy confers an advantage for overall survival (OAS), and progression free survival (PFS); to assess the incidence of relapses over standard pelvic radiotherapy; and to evaluate the related toxi...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Hadaad, Hend Ahmed, Wahba, Hanan Ahmed, Gamal, Anas Mohamed, Dawod, Tamer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643665/
https://www.ncbi.nlm.nih.gov/pubmed/23691474
http://dx.doi.org/10.7497/j.issn.2095-3941.2012.03.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643665/
https://www.ncbi.nlm.nih.gov/pubmed/23691474
http://dx.doi.org/10.7497/j.issn.2095-3941.2012.03.003

Ejemplares similares